Cyclerion Therapeutics Inc (CYCN)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$3.36

-0.89 (-20.94%)

Market Cap: $15.73M

Last updated: Sep 08, 2026 at 7:42 PM ET

Earnings

Performance (10Y)

Beat Rate

56%(9/16)

Avg Surprise

-97.21%

Streak

1 Q

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Jun 30, 2026Jun 26 Reported Aug 4, 2026Reported Aug 4	$-0.41	N/A	-	N/A	Beat	-	-	+26.7%
Dec 31, 2025Dec 25 Reported Mar 25, 2026Reported Mar 25	$-0.19	$-0.38	-	+50.00%	Beat	0	No revisions (30d)	-191.3%
Sep 30, 2025Sep 25 Reported Nov 12, 2025Reported Nov 12	$-0.30	$0.00	-	N/A	Miss	-	-	-4.8%
Jun 30, 2025Jun 25 Reported Aug 5, 2025Reported Aug 5	$-0.11	N/A	-	N/A	Beat	-	-	+79.1%
Mar 31, 2025Mar 25 Reported May 6, 2025Reported May 6	$-0.56	N/A	-	N/A	Beat	-	-	+9.6%
Dec 31, 2024Dec 24 Reported Mar 4, 2025Reported Mar 4	$0.21	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	+130.4%
Sep 30, 2024Sep 24 Reported Nov 14, 2024Reported Nov 14	$-0.29	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	-109.2%
Jun 30, 2024Jun 24 Reported Aug 7, 2024Reported Aug 7	$-0.53	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	+71.3%
Mar 31, 2024Mar 24 Reported May 7, 2024Reported May 7	$-0.62	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	+80.7%
Dec 31, 2023Dec 23 Reported Mar 5, 2024Reported Mar 5	$-0.68	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	-302.8%
Sep 30, 2023Sep 23 Reported Nov 13, 2023Reported Nov 13	$3.11	N/A	-	N/A	Beat	-	-	+164.7%
Jun 30, 2023Jun 23 Reported Jul 28, 2023Reported Jul 28	$-1.83	$-0.28	-	-554.36%	Miss	-	-	+70.4%
Mar 31, 2023Mar 23 Reported May 11, 2023Reported May 11	$-3.20	$-0.30	$-0.30 - $-0.30	-965.23%	Miss	0	1 0 30d	+46.7%
Dec 31, 2022Dec 22 Reported Mar 22, 2023Reported Mar 22	$-0.17	$-0.29	$-0.29 - $-0.29	+41.38%	Beat	0	1 0 30d	+48.5%
Sep 30, 2022Sep 22 Reported Nov 3, 2022Reported Nov 3	$-4.80	$-7.00	$-7.04 - $-6.96	+31.43%	Beat	2	No revisions (30d)	+7.7%
Jun 30, 2022Jun 22 Reported Aug 9, 2022Reported Aug 9	$-6.20	$-6.80	$-6.84 - $-6.76	+8.82%	Beat	2	No revisions (30d)	-1277.8%
Mar 31, 2022Mar 22 Reported May 4, 2022Reported May 4	$-6.00	$-7.20	$-7.20 - $-7.20	+16.67%	Beat	1	No revisions (30d)	-1438.5%
Dec 31, 2021Dec 21 Reported Feb 24, 2022Reported Feb 24	$-0.33	$-0.30	$-0.30 - $-0.30	-10.00%	Miss	0	No revisions (30d)	+97.0%
Sep 30, 2021Sep 21 Reported Nov 9, 2021Reported Nov 9	$-5.20	$-5.80	-	+10.34%	Beat	-	-	+55.9%
Jun 30, 2021Jun 21 Reported Jul 29, 2021Reported Jul 29	$-0.45	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	+96.8%
Mar 31, 2021Mar 21 Reported Apr 30, 2021Reported Apr 30	$-0.39	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	+46.6%
Dec 31, 2020Dec 20 Reported Feb 25, 2021Reported Feb 25	$-11.00	$-3.80	$-3.80 - $-3.80	-189.47%	Miss	1	No revisions (30d)	+42.1%
Sep 30, 2020Sep 20 Reported Nov 5, 2020Reported Nov 5	$-11.80	$-11.20	$-11.20 - $-11.20	-5.36%	Miss	1	1 0 30d	+41.0%
Jun 30, 2020Jun 20 Reported Aug 3, 2020Reported Aug 3	$-14.00	$-17.26	$-17.26 - $-17.26	+18.89%	Beat	1	No revisions (30d)	+40.7%
Mar 31, 2020Mar 20 Reported May 4, 2020Reported May 4	$-0.73	$-0.87	$-0.87 - $-0.87	+16.09%	Beat	1	No revisions (30d)	+20.7%
Dec 31, 2019Dec 19 Reported Mar 12, 2020Reported Mar 12	$-19.00	$-17.84	$-17.84 - $-17.84	-6.50%	Miss	1	No revisions (30d)	-854.8%
Sep 30, 2019Sep 19 Reported Nov 12, 2019Reported Nov 12	$-20.00	$-25.98	$-25.98 - $-25.98	+23.02%	Beat	1	No revisions (30d)	-465.0%
Jun 30, 2019Jun 19 Reported Aug 12, 2019Reported Aug 12	$-23.60	$-16.72	$-16.72 - $-16.72	-41.15%	Miss	1	No revisions (30d)	-
Mar 31, 2019Mar 19 Reported Apr 23, 2019Reported Apr 23	$-0.92	N/A	-	N/A	Beat	-	-	-
Dec 31, 2018Dec 18 Reported Mar 11, 2019Reported Mar 11	$-1.99	$0.00	-	N/A	Miss	-	-	-
Sep 30, 2018Sep 18 Reported Oct 9, 2018Reported Oct 9	$-3.54	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	N/A	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	-359.20%
ROE	-98.20%	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	N/A
Current Ratio	N/A	Quick Ratio	N/A
Trading Statistics
Beta	1.75	Avg Volume	N/A
52-Week High	$59.36	52-Week Low	$7.19

Technical Indicators Dashboard

Moving Averages

SMA 10$4.09

SMA 20$4.01

SMA 50$3.75

SMA 200$2.56

EMA 10$4.06

EMA 20$3.99

EMA 50$3.75

EMA 200$3.00

MACD

Line: 0.12Signal: 0.14Hist: -0.02

ADX

ADX: 36.3+DI: 24.3-DI: 29.6

Aroon & PSAR

Aroon Up92.0

Aroon Down100.0

PSAR$5.19

Bollinger Bands

Upper Band$4.69

Lower Band$3.34

%B Position3360%(Upper)

Band Width0.02

RSI (14-Day)

Neutral

41.2

Momentum Oscillators

Stoch %K50.6

Stoch %D68.2

Williams %R-77.2

ROC (10d)-14.5%

Momentum-0.57

CCI (20d)-225.6

MFI (14d)43.7

Volatility Measures

ATR (14d)$0.51(15.1%)

StdDev (20d)0.34

Hist Vol127.5%(High)

Volume Flow

VWAP$3.34

OBV348.4M

AD Line-119.2M

CMF (20d)-0.098

Volume Metrics

Avg Vol (20d)96.6K

Vol Ratio4.5x(High)

VWMA (20d)$3.94

Pivot Points

R3$4.94

R2$4.74

R1$4.49

Pivot Point$4.29

S1$4.04

S2$3.84

S3$3.59

Advanced Oscillators

TSI12.16

Ultimate Osc44.2

KST117.96

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$1.20M	$875,000	$93,000	$81,000	$1.81M	$194,000	$0	$0	$0	$0
Cost of Revenue	$0	$0	N/A	$0	$0	$0	N/A	$0	$0	$0	N/A	$0
Gross Profit	$0	$0	$1.20M	$875,000	$93,000	$81,000	$1.81M	$194,000	$0	$0	N/A	$0

Operating Expenses	$1.77M	$3.21M	$1.86M	$1.88M	$1.76M	$1.54M	$1.30M	$1.32M	$1.38M	$1.62M	$1.80M	$6.01M
R&D	$0	$730,000	$519,000	$348,000	$56,000	$36,000	$56,000	$81,000	$105,000	$44,000	$24,000	$580,000
SG&A	$1.77M	$2.48M	$1.34M	$1.53M	$1.71M	$1.50M	$1.25M	$1.24M	$1.28M	$1.57M	$1.77M	$2.13M
Operating Income	$-1,771,000	$-3,209,000	$-838,000	$-1,006,000	$-1,672,000	$-1,457,000	$502,000	$-1,128,000	$-1,384,000	$-1,618,000	$-1,796,000	$-6,015,000

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-1,755,000	$-3,177,000	$692,000	$-976,000	$-324,000	$-1,429,000	$530,000	$-723,000	$-1,322,000	$-1,542,000	$-1,545,000	$-5,908,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-1,755,000	$-3,177,000	$-799,000	$-976,000	$-324,000	$-1,429,000	$530,000	$-723,000	$-1,322,000	$-1,542,000	$-1,694,000	$7.57M

EBITDA	$-1,755,000	$-3,177,000	$518,000	$-976,000	$-324,000	$-1,429,000	$530,000	$-723,000	$-1,322,000	$-1,542,000	$-1,796,000	$-5,908,000
EBIT	$-1,755,000	$-3,177,000	$518,000	$-976,000	$-324,000	$-1,429,000	$530,000	$-723,000	$-1,322,000	$-1,542,000	$-1,796,000	$-5,908,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about CYCN

News

Cyclerion Shareholders Approve Key Measures for Korsana Merger

Cyclerion Therapeutics shareholders approved key measures for its planned merger with Korsana Biosciences, including a significant new share issuance to Korsana holders...

TipRanks•Aug 27, 2026 2:24 PM ET8/27/26•Somewhat-Bullish

Cyclerion Therapeutics - Sets Sept 4, 2026 As Record Date For Cvr Distribution In Korsana Merger - SEC Filing

Cyclerion Therapeutics announced that it has set September 4, 2026, as the record date for the Contingent Value Right (CVR) distribution in connection with its merger with Korsana. This information was disclosed...

TradingView•Aug 25, 2026 4:43 PM ET8/25/26•Neutral

Cyclerion Therapeutics (CYCN) sets CVR date for Korsana merger

Cyclerion Therapeutics (CYCN) has announced that September 4, 2026, will be the record date for the distribution of contingent value rights (CVRs) to shareholders in connection with its planned merger with Korsana...

Stock Titan•Aug 25, 2026 4:43 PM ET8/25/26•Neutral

Cyclerion (NASDAQ: CYCN) CFO buys 25,000 shares in cash exercise

Cyclerion Therapeutics, Inc.'s Chief Financial Officer, Rhonda M. Chicko, exercised options to purchase 25,000 shares of common stock at an exercise price of $2.355 per share. The options were granted in August 2025...

Stock Titan•Aug 18, 2026 5:13 PM ET8/18/26•Neutral

Cyclerion (CYCN) CEO uses cashless exercise, forfeits 48,629 options

Cyclerion Therapeutics, Inc. CEO Regina Margaret Graul exercised an employee stock option for 55,849 shares at $3.30 per share on August 14...

Stock Titan•Aug 18, 2026 5:13 PM ET8/18/26•Neutral

CYCN Profitability: Margins, ROIC and FCF

Operating margin: -359.2%
Net margin: 0.0%
ROE: -98.2%

CYCN Competitors

Company	Ticker
Psyence Biomedical Ltd. Common Shares	PBM
Heart Test Laboratories Inc. Common Stock	HSCS
Concord Medical Services Holdings	CCM
Biocardia Inc	BCDA
Dyadic International Inc	DYAI
Marker Therapeutics Inc	MRKR
Jasper Therapeutics Inc	JSPR
Tscan Therapeutics Inc	TCRX

Sector: Healthcare

CYCN Bull Case vs Bear Case

Bear case

CYCN beat EPS estimates in 25.0% of its last 8 reported quarters.
CYCN's quarterly revenue changed -43.2% year over year.

CYCN Earnings: Beat Rate and Next Report

Beat rate: 2 of 8 quarters (25.0%)
Average surprise: -252.2%

Frequently Asked Questions About CYCN

Does CYCN pay dividends?

Cyclerion Therapeutics Inc (CYCN) does not currently pay a regular dividend.

What is CYCN's market cap?

Cyclerion Therapeutics Inc (CYCN) has a market capitalization of $15.73M with a current stock price of $3.36.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In